4.16k followers • 30 symbols Watchlist by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies.
Curated by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies. These companies develop specialty drugs and treatments for various diseases and medical conditions. Although there are risks associated with the success of the drug, those that succeed tend to have a strong series of earnings growth over a period of time, especially when they are backed by patents.
The list includes stocks priced at $5 or more with a three month average daily trading volume in excess of 200,000 shares. This list is generated daily and sorted by market cap; the gains are based on the latest closing price and limited to the top 30 stocks that meet the criteria.
This watchlist is similar to a discontinued watchlist called Battling Cancer.
Yahoo Finance employs sophisticated algorithms to monitor and detect trends in the Global Financial Markets. We bring these insights to you in the form of watchlists.
Find other winning investment ideas with the Yahoo Finance Screener.How are these weighted?
The stocks in this watchlist are weighted equally.
|Watchlist||Change Today||1 Month Return||1 Year Return||Total Return|
|Biotech and Drug Stocks||-0.50%||-||-||-|
|Symbol||Company Name||Last Price||Change||% Change||Market Time||Volume||Avg Vol (3 month)||Market Cap|
|JNJ||Johnson & Johnson||161.98||-3.24||-1.96%||4:00 PM EDT||12.99M||7.16M||426.56B|
|RHHBY||Roche Holding AG||47.08||-0.41||-0.86%||4:00 PM EDT||1.61M||1.41M||328.85B|
|PFE||Pfizer Inc.||38.81||-0.67||-1.70%||4:02 PM EDT||33.21M||26.94M||217.25B|
|NVS||Novartis AG||93.01||-1.14||-1.21%||4:00 PM EDT||1.31M||1.89M||211.06B|
|LLY||Eli Lilly and Company||218.55||-3.66||-1.65%||4:05 PM EDT||3.19M||3.33M||209.59B|
|ABBV||AbbVie Inc.||113.12||-1.78||-1.55%||4:03 PM EDT||6.95M||6.62M||199.79B|
|MRK||Merck & Co., Inc.||76.61||-0.62||-0.80%||4:02 PM EDT||16.35M||12.17M||193.98B|
|NVO||Novo Nordisk A/S||82.28||-0.49||-0.59%||4:00 PM EDT||886.93k||908.32k||191.19B|
|AZN||AstraZeneca PLC||58.37||+0.02||+0.03%||4:00 PM EDT||14.11M||8.28M||155.23B|
|BMY||Bristol-Myers Squibb Company||66.47||-0.30||-0.45%||4:00 PM EDT||15.04M||10.46M||148.42B|
|AMGN||Amgen Inc.||238.68||-2.08||-0.86%||4:00 PM EDT||5.56M||2.64M||137.13B|
|SNY||Sanofi||52.86||-0.38||-0.71%||4:00 PM EDT||5.68M||1.32M||133.96B|
|GSK||GlaxoSmithKline plc||39.84||-0.73||-1.80%||4:00 PM EDT||9.92M||4.64M||100.23B|
|ZTS||Zoetis Inc.||185.39||-1.05||-0.56%||4:06 PM EDT||2.96M||1.78M||88.02B|
|GILD||Gilead Sciences, Inc.||66.61||-0.61||-0.91%||4:00 PM EDT||11.46M||7.18M||83.54B|
|MRNA||Moderna, Inc.||199.19||-3.28||-1.62%||4:00 PM EDT||6.66M||9.32M||79.98B|
|BAYRY||Bayer Aktiengesellschaft||15.73||-0.24||-1.47%||3:59 PM EDT||217.57k||387.16k||62.14B|
|BIIB||Biogen Inc.||388.44||+4.92||+1.28%||4:00 PM EDT||2.87M||1.75M||58.48B|
|REGN||Regeneron Pharmaceuticals, Inc.||537.92||+1.91||+0.36%||4:00 PM EDT||914.79k||815.33k||57.31B|
|TAK||Takeda Pharmaceutical Company Limited||16.55||-0.36||-2.13%||4:00 PM EDT||4.43M||2.42M||52.79B|
|BNTX||BioNTech SE||212.42||-1.78||-0.83%||4:00 PM EDT||2.26M||3.04M||51.30B|
|VRTX||Vertex Pharmaceuticals Incorporated||187.85||-0.51||-0.27%||4:00 PM EDT||3.52M||1.98M||48.63B|
|ALXN||Alexion Pharmaceuticals, Inc.||180.69||+0.72||+0.40%||4:00 PM EDT||3.91M||2.07M||40.06B|
|SGEN||Seagen Inc.||156.31||+2.93||+1.91%||4:00 PM EDT||1.14M||894.35k||28.37B|
|GMAB||Genmab A/S||42.92||-0.61||-1.40%||4:00 PM EDT||6.15M||527.94k||28.05B|
|RPRX||Royalty Pharma plc||44.02||-0.11||-0.25%||4:00 PM EDT||7.11M||1.95M||26.73B|
|HZNP||Horizon Therapeutics Public Limited Company||94.61||+2.47||+2.68%||4:00 PM EDT||6.86M||1.65M||21.27B|
|ALNY||Alnylam Pharmaceuticals, Inc.||176.89||+4.64||+2.69%||4:00 PM EDT||1.52M||528.49k||20.79B|
|CTLT||Catalent, Inc.||108.61||-1.95||-1.76%||4:03 PM EDT||1.15M||1.00M||18.50B|
|INCY||Incyte Corporation||83.96||+0.83||+1.00%||4:00 PM EDT||2.07M||1.21M||18.46B|
FOSTER CITY, Calif., Jun 21, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that more than 70 abstracts from the company’s liver disease programs will be presented at The International Liver Congress™ 2021 (ILC) taking place from June 23-26. The breadth of data reflects Gilead’s continued commitment to liver disease, including the recent expansion into chronic hepatitis delta virus (HDV), with Hepcludex® (bulevertide) as the first-in-class treatment for people with HDV conditionally
Company Announcement COPENHAGEN, Denmark; June 21, 2021 – Genmab A/S (Nasdaq: GMAB). On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant exercises and to honor our commitments under our Restricted Stock Units program. The share buy-back program is expected to be completed no later than June 30, 2021 and comprises up to 200,000 shares. The following transactions were executed under the program from June 14, 2021, to June 18, 2021: No.
(Bloomberg) -- In a country where workplaces play an outsized role in people’s lives, Japan is betting that enlisting its largest corporations to roll out Covid-19 vaccines will add fuel to a much-scrutinized inoculation drive.Still grappling with a rollout that’s deployed only enough doses to cover 11% of the population, the Japanese government is allowing its biggest corporate brand names and employers like Toyota Motor Corp., SoftBank Group Corp., and Nomura Holdings Inc. to administer shots